SCHEMBL5135705

SCHEMBL5135705

CCCCN(Cc1cccc(OC)c1)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 1/20 0.45
CAMKK2 Q96RR4 1/20 0.45
C5AR1 P21730 1/20 0.44
TLR7 Q9NYK1 1/20 0.41
BCHE P06276 3/20 0.40
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
CNR2 P34972 1/20 0.40
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
MAPT P10636 1/20 0.39
F2R P25116 3/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TSHR P16473 1/20 0.39
ATP4A P20648 1/20 0.39
ATP4B P51164 1/20 0.39
CRHR1 P34998 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5170566 0.97 CALM1 (0.43) CALM1CAMKK2C5AR1TLR7BCHE
SCHEMBL5134931 0.97 CALM1 (0.44) CALM1CAMKK2C5AR1TLR7BCHE
SCHEMBL5137491 0.96 CALM1 (0.45) CALM1CAMKK2C5AR1TLR7BCHE
SCHEMBL5074293 0.96 CALM1 (0.45) CALM1CAMKK2C5AR1TLR7BCHE
SCHEMBL5137571 0.95 POLB (0.42) CALM1CAMKK2C5AR1TLR7HSP90AA1
SCHEMBL5072289 0.95 ABCB1 (0.42) CALM1CAMKK2C5AR1TLR7BCHE
SCHEMBL5135433 0.94 C5AR1 (0.46) CALM1CAMKK2C5AR1TLR7BCHE
SCHEMBL5135383 0.93 C5AR1 (0.45) CALM1CAMKK2C5AR1TLR7BCHE
SCHEMBL5138089 0.93 TSHR (0.46) C5AR1BCHETSHRATP4AATP4B
SCHEMBL649782 0.92 C5AR1 (0.44) C5AR1BCHENR1H3MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed